Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells.

Bodogai M, Moritoh K, Lee-Chang C, Hollander CM, Sherman-Baust CA, Wersto RP, Araki Y, Miyoshi I, Yang L, Trinchieri G, Biragyn A.

Cancer Res. 2015 Sep 1;75(17):3456-65. doi: 10.1158/0008-5472.CAN-14-3077. Epub 2015 Jul 16.

2.

A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.

Sherman-Baust CA, Kuhn E, Valle BL, Shih IeM, Kurman RJ, Wang TL, Amano T, Ko MS, Miyoshi I, Araki Y, Lehrmann E, Zhang Y, Becker KG, Morin PJ.

J Pathol. 2014 Jul;233(3):228-37. doi: 10.1002/path.4353.

3.

The growth response to androgen receptor signaling in ERĪ±-negative human breast cells is dependent on p21 and mediated by MAPK activation.

Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M, Wang GM, Jelovac D, Weeraratna A, Sherman Baust CA, Morin PJ, Toubaji A, Meeker A, De Marzo AM, Lewis G, Subhawong A, Argani P, Park BH.

Breast Cancer Res. 2012 Feb 9;14(1):R27.

4.

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin.

Sherman-Baust CA, Becker KG, Wood Iii WH, Zhang Y, Morin PJ.

J Ovarian Res. 2011 Dec 5;4(1):21. doi: 10.1186/1757-2215-4-21.

5.

Age-related changes of claudin expression in mouse liver, kidney, and pancreas.

D'Souza T, Sherman-Baust CA, Poosala S, Mullin JM, Morin PJ.

J Gerontol A Biol Sci Med Sci. 2009 Nov;64(11):1146-53. doi: 10.1093/gerona/glp118. Epub 2009 Aug 19.

6.

Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer.

Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ.

BMC Cancer. 2009 Jul 20;9:244. doi: 10.1186/1471-2407-9-244.

7.

MicroRNA expression and identification of putative miRNA targets in ovarian cancer.

Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IeM, Zhang Y, Wood W 3rd, Becker KG, Morin PJ.

PLoS One. 2008 Jun 18;3(6):e2436. doi: 10.1371/journal.pone.0002436.

8.

Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers.

Rangel LB, Agarwal R, Sherman-Baust CA, Mello-Coelho Vd, Pizer ES, Ji H, Taub DD, Morin PJ.

Cancer Biol Ther. 2004 Oct;3(10):1021-7. Epub 2004 Oct 2.

PMID:
15467430
9.

Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression.

Rangel LB, Sherman-Baust CA, Wernyj RP, Schwartz DR, Cho KR, Morin PJ.

Oncogene. 2003 Oct 16;22(46):7225-32.

PMID:
14562052
10.

Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells.

Sherman-Baust CA, Weeraratna AT, Rangel LB, Pizer ES, Cho KR, Schwartz DR, Shock T, Morin PJ.

Cancer Cell. 2003 Apr;3(4):377-86.

11.

Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer.

Sawiris GP, Sherman-Baust CA, Becker KG, Cheadle C, Teichberg D, Morin PJ.

Cancer Res. 2002 May 15;62(10):2923-8.

12.

Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer.

Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ, Morin PJ.

Cancer Res. 2000 Nov 15;60(22):6281-7.

13.

Evidence for the colonic origin of ovarian cancer cell line SW626.

Furlong MT, Hough CD, Sherman-Baust CA, Pizer ES, Morin PJ.

J Natl Cancer Inst. 1999 Aug 4;91(15):1327-8. No abstract available.

PMID:
10433623

Supplemental Content

Loading ...
Support Center